Report cover image

Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others (RANK ligand inhibitors, etc.)), By Disease Indication (Multiple Myeloma, Osteosarcoma, Chondrosarcoma, and Ewings Sarcoma), By Distribution Channel, Hospita

Publisher Coherent Market Insights
Published Mar 10, 2025
Length 204 Pages
SKU # CMI20004438

Description

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.

Key features of the study:
  • This report provides in-depth analysis of the global bone cancer drug market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bone cancer drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market
Detailed Segmentation:
  • Global Bone Cancer Drug Market, By Type:
  • Multiple Myeloma
  • Osteosarcoma
  • Chondrosarcoma
  • Ewing’s Sarcoma
  • Global Bone Cancer Drug Market, By Treatment Type:
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Surgery
  • Global Bone Cancer Drug Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Bone Cancer Drug Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • Company Profiles
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceutical

Table of Contents

204 Pages
1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraintsa
Opportunities
Market Trends
Regulatory Scenario
New Product Launches/Approvals
Merger, Acquisition and Collaboration Scenario
PEST Analysis
PORTER’s Analysis
4. Global Bone Cancer Drugs Market – COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Bone Cancer Drugs Market, By Drug Type, 2020– 2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021–2032
Segment Trends
Antimetabolites
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Anthracyclines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Others (RANK ligand inhibitors, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (US$ Mn)
6. Global Bone Cancer Drugs Market, By Disease Indication, 2020 – 2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021–2032
Segment Trends
Multiple Myeloma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (US$ Mn)
Osteosarcoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (US$ Mn)
Chondrosarcoma
Introduction
Ewing’s Sarcoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
7. Global Bone Cancer Drugs Market, By Distribution Channel, 2020 – 2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021–2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (US$ Mn)
8. Global Bone Cancer Drugs Market, By Region, 2020 – 2032, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Region, 2021–2032
Segment Trends
North America
Market Size and Forecast,and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020–2032, (US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Company Profiles
Advaxis, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Cellectar Biosciences, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
OPKO Health, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Amgen Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Eli Lilly and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Debiopharm Group
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Merck & Co
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Bristol-Myers Squibb Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Takeda Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Teva Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Analyst Views
10. Section
References
Research Methodology
About us and Sales Contact
*Browse 36 market data tables and 26 figures on “Global Bone Cancer Drugs Market” – Global forecast to 2032

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us